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Essentials
• Platelet reactivity is correlated with thrombotic risk after percutaneous coronary intervention (PCI).
• Hematocrit (HCT) is associated with platelet reactivity
as measured with the VerifyNow P2Y 12 assay.
• We tested a formula proposed to correct VerifyNow measurements for HCT in 978 PCI patients.
• Correcting platelet reactivity for HCT did not improve the prediction of thrombotic events after PCI.
Summary. Background: High on-treatment platelet reactivity is predictive for the occurrence of atherothrombotic events following percutaneous coronary interventions (PCIs). A low hematocrit (HCT) value is associated with higher platelet reactivity values, expressed in P2Y 12 reaction units (PRU), as measured with the VerifyNow P2Y 12 assay. However, it is suggested that this is only an in vitro phenomenon. Objective: To determine whether adjusting PRU for HCT improves the predictive value for thrombotic events following PCI. Material and methods: The VerifyNow P2Y 12 assay was performed in clopidogreltreated patients undergoing non-urgent PCI included in a prospective cohort study. PRU values were corrected for HCT with a formula proposed in recent literature. Receiver operating characteristic (ROC) curves were made to determine the optimal cut-off values to predict the occurrence of the primary endpoint, a composite of allcause death and non-fatal myocardial infarction, stent thrombosis and ischemic stroke, during 1 year of followup. The chi-squared test was performed to determine whether correcting PRU for HCT improved the prediction of the primary endpoint. Results: A total of 978 patients were analyzed. A negative correlation between PRU and HCT was observed (R 2 = 0.104). The optimal cut-off value for the corrected PRU was 215. ROC analyses showed that prediction of the primary endpoint did not differ for the corrected PRU (area under the curve,
Introduction
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 inhibitor is used to reduce the incidence of atherothrombotic events, such as stent thrombosis, in patients undergoing percutaneous coronary intervention (PCI) with stent implantation [1] [2] [3] . Inadequate inhibition of blood platelets by treatment with a P2Y 12 inhibitor, such as clopidogrel, results in high on-treatment platelet reactivity (HPR), which can be assessed with platelet function tests (e.g. the VerifyNow P2Y 12 assay) [4, 5] and is a predictor of thrombotic events after a PCI [6] [7] [8] [9] .
The results of the VerifyNow P2Y 12 assay are expressed in P2Y 12 Reaction Units (PRU). Kakouros et al. [10] and Voisin et al. [11] showed that the PRU value is negatively correlated with hematocrit (HCT), which might be a relevant factor to account for when interpreting the test results. Because this correlation does not appear with light transmittance aggregometry (LTA), which is a different platelet function test, it is suggested that this is only an in vitro phenomenon associated with the VerifyNow P2Y 12 assay [10] .
In contrast to the VerifyNow P2Y 12 assay, which requires citrated whole blood, blood used for the LTA has to be centrifuged before platelet reactivity is assessed. Sodium citrate could influence whole blood assays, because it acts as an anticoagulant by binding calcium. Sodium citrate does not enter red blood cells and therefore its concentration in plasma is dependent on HCT levels. A low HCT renders a relative excess of calcium if a constant amount of citrate is used. With more calcium present, more coagulation could take place and HCT could thereby influence platelet aggregation measured by the VerifyNow P2Y 12 test. In a publication by Kakouros et al. [10] , the authors proposed correcting platelet reactivity measured with the VerifyNow P2Y 12 assay for deviations in HCT. After correcting for HCT, the incidence of HPR as determined with several different cut-off values was reduced by 13-39%. The authors suggested that correcting PRU for HCT might increase the predictive value of HPR for thrombotic events during follow-up. In this analysis, we aimed to determine if PRU corrected for HCT is a better predictor of thrombotic events after PCI than uncorrected PRU.
Material and methods

Data from the Do Platelet Function Assays Predict
Clinical Outcomes in Clopidogrel-Pretreated Patients Undergoing Elective PCI (POPular) study was used to asses the impact of correction for HCT on the prediction of atherothrombotic events after PCI. The study procedures of this prospective cohort study are summarized below and can be found in a previous publication [12] .
Study population
Patients undergoing non-urgent PCI at the St Antonius Hospital in Nieuwegein were included in this study between December 2005 and December 2007. Adequate clopidogrel pre-treatment, which was defined as a maintenance dose of 75 mg a day for ≥5 days or a loading dose of 300 mg ≥24 h or 600 mg ≥4 h before PCI, was required for inclusion. Exclusion criteria were concomitant use of medication known to affect platelet function other than aspirin and clopidogrel (i.e. non-steroidal antiinflammatory agents, dipyridamole or glycoprotein IIb/ IIIa inhibitors before blood sampling), a known platelet function disorder or a whole blood platelet count of less than 150 9 10 9 /L. This study was approved by the local institutional medical ethical committee and was performed according to the guidelines of the revised version of the Declaration of Helsinki. Written informed consent was obtained from all patients.
Blood sampling and platelet function testing
Before PCI and before the administration of heparin, blood was drawn from the femoral or radial artery through a 6 or 7 French sheath. The first 5 mL of blood was discarded in order to prevent dilution of the blood with infused fluids. HCT values were determined before the procedure. For the VerifyNow P2Y 12 assay, 3 mL of whole blood was collected in a 3.2% citrate tube. A higher PRU value means higher platelet reactivity [13] .
Follow-up and primary endpoint
Follow-up was performed up to 1 year after PCI. The primary endpoint was a composite of all-cause death, non-fatal acute myocardial infarction, non-fatal stent thrombosis and non-fatal ischemic stroke. Definitions can be found in the original publication [12] .
Statistical analysis
Continuous data were reported as mean AE standard deviation, whereas categorical data were reported as frequencies with the corresponding percentage. Missing data were not imputed. Linear regression was conducted to determine if there was a correlation between the PRU and HCT. PRU values were corrected for HCT with the formula composed by Kakouros et al. (corrected PRU = uncorrected PRU + ((HCT(%) À 42) * 7.5)) and a new correction coefficient calculated with data from our study cohort. In order to determine this new correction coefficient, linear regression was performed with VerifyNow BASE and HCT values. BASE is not influenced by the use of clopidogrel as it represents maximum platelet reactivity. The correction coefficient was defined as the slope of the regression line. To evaluate the predictive value of the uncorrected (PRU uncorr ) and corrected PRU (PRU corr ) for the primary endpoint at 1 year follow-up, a receiver operating characteristic (ROC) curve was calculated for uncorrected and corrected PRU. ROC curves were used to determine a new optimal cut-off value to predict the primary endpoint, defined as the point with the highest combined sensitivity and specificity. Bootstrapping was used to compare the ROC curves. In further analyses, a PRU value higher than or equal to the optimal cut-off value was deemed HPR. The McNemar test was used for paired dichotomous data to compare the amount of misclassifications with the PRU corr value with the new cut-off value and the amount with the PRU uncorr with the old cut-off value. All statistical analyses were performed using SPSS 22.0, except for the generation and comparison of the ROC curves, for which R version 3.0.2 was used. All analyses were two-sided, with a P-value <0.05 considered as significant.
Results
The POPular study included a total of 1069 PCI patients. One-year follow-up was available for all patients. A total of 978 patients were selected for this analysis based on availability of PRU and HCT values. The baseline characteristics of these patients are presented in Table 1 . Table 2 shows the incidence of thrombotic events during 1 year of follow-up. PRU was negatively correlated with HCT (R 2 =0.104; P<0.0001) (see Fig. 1 ), suggesting that a lower HCT would result in a higher PRU and vice versa.
The mean and standard deviation of PRU uncorr and PRU corr (formula of Kakouros et al. [10] ) values were 210 AE 76 and 204 AE 72, respectively.
The primary endpoint and correction of PRU Figure 2 depicts the ROC curve of the occurrence of the primary endpoint in relation to the PRU uncorr (dotted line) and PRU corr (straight line). The optimal cut-off value for PRU uncorr was 236, with an area under the curve (AUC) of 0.61, sensitivity of 0.57 and specificity of 0.64. The optimal cut-off value for PRU corr was 215 (AUC, 0.61; sensitivity, 0.69; specificity, 0.53).The two ROC curves did not significantly differ (P = 0.444).
Patients were reclassified into HPR and no-HPR groups using the PRU corr . This increased the rate of HPR from 38.1% to 49.4%. The distribution of patients with and without events is shown in Table 3 .
We defined a misclassification as a patient who was assigned to the no-HPR group who experienced the primary endpoint or a patient who was assigned to the HPR group who not experience the primary endpoint. Correcting the PRU for HCT led to the misclassification of 450 patients (46.0%), instead of 358 patients (36.6%, P < 0.001) using PRU uncorr .
A significant difference was found between the occurrence of the primary endpoint in the no-HPR and HPR groups determined with PRU uncorr ( difference was also found with the PRU corr and corresponding cut-off value (OR, 2.46; 95% CI, 1.55-4.00; P < 0.001).
Determination of a new correction coefficient
Based on BASE and HCT data ( Figure S1 ), a new correction coefficient was determined: 6.7. This led to the following formula: corrected PRU = uncorrected PRU + (HCT (%) À 42) * 6.7. The ROC analysis for PRU corr using this correction coefficient revealed that a cut-off of 216 PRU best predicted the primary endpoint, with an AUC of 0.598, a sensitivity of 0.67 and a specificity of 0.53. Table S1 shows the classification of patients into an HPR and an NPR group based on their corrected and uncorrected P2Y12 reaction unit (PRU) value and the incidence of the primary endpoint in each of these groups. A significant difference was found between the occurrence of the primary endpoint in the NPR and HPR groups (5.8% vs. 12.1%; OR, 2.24; 95% CI, 1.42-3.61; P < 0.001).
Discussion
The most important findings in this study were: (i) a negative correlation between PRU and HCT was found; (ii) when PRU was corrected for HCT according to the formula proposed by Kakouros et al. [10] , the optimal cutoff value for the VerifyNow P2Y 12 assay to predict atherothrombotic events after PCI was 215 PRU; and (iii) the predictive value of PRU for thrombotic events during 1-year follow-up after PCI did not improve with correction for HCT, either based on the formula proposed by Kakouros et al. or a correction coefficient determined in this study.
Multiple studies have shown a negative correlation between the VerifyNow P2Y 12 assay's PRU and HCT [10, 11, 14] . However, other assays such as Multiplate and thromboelastography (TEG) are also influenced by HCT levels [15] . Although HCT was not correlated with platelet reactivity measured with LTA in studies by Kakouros et al. or Pendyala et al. [10, 14] , Toma et al. did find a negative correlation between HCT and platelet reactivity measured by LTA [16] .
Correcting platelet reactivity test results for HCT only makes sense if the negative correlation is an artificial effect related to the assays instead of a true biological phenomenon. On the one hand, multiple arguments can be made that this correlation is only an in vitro phenomenon. Kakouros et al. observed that HCT had no effect on the magnitude of change in ADP-induced platelet aggregation after clopidogrel loading as compared with before clopidogrel loading, as measured with the VerifyNow P2Y 12 assay, whole blood aggregometry or LTA. Furthermore, HCT was an independent predictor of PRU after clopidogrel loading in multivariate modeling, which included LTA results to account for the clopidogrel-induced changes in intrinsic platelet reactivity. Prior studies have also shown that changes in HCT can affect calcium concentration in citrated blood used for the assays, such as the VerifyNow P2Y 12 assay, and thereby influence the ADP-induced aggregation [17, 18] . A lower HCT would lead to relatively less citrate and therefore higher calcium concentrations in the tested sample. When the citrate concentrations were adjusted for HCT, the difference in platelet reactivity was no longer evident [19] . On the other hand, multiple arguments support the concept of an in vivo correlation between HCT and HPR. The anemic milieu is often characterized by the presence of inflammatory biomarkers such as fibrinogen, von Willebrand factor and inflammatory cytokines, which are associated with increased platelet reactivity [20] . Moreover, potential bone marrow hyperactivity as a result of the anemic condition could lead to a release of immature platelets, which are associated with lower responsiveness to clopidogrel and greater thrombogenic potential [21] . So a lower HCT could lead to higher platelet reactivity. However, a lower concentration of red blood cells (and therefore HCT) should also lead to a diminished concentration of platelets at the vessel wall and could thereby decrease platelet reactivity [22, 23] . We conclude that the current study does not support a relationship between HCT and thrombotic events.
Study limitations
Kakouros et al. calculated a formula to correct PRU for HCT by using pre-and post-clopidogrel BASE and HCT values. Only post-clopidogrel BASE and HCT values were available in our study and we were therefore unable to replicate the calculation of the formula in our study cohort. Instead we both used the formula that was proposed by Kakouros et al. and calculated our own correction coefficient to correct PRUs for HCT. Another limitation is that we do not know the reason for the lower HCT values in some of the patients in this cohort. Anemia could be the manifestation of an underlying chronic disease state or an acute process related to bleeding.
Conclusion
A negative correlation between platelet reactivity measured with the VerifyNow P2Y 12 assay and HCT was found. However, correcting PRU for HCT does not improve the prediction of thrombotic events following non-urgent PCI. 
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